• QPRT Drives Breast Cancer Invasion via PLC-Dependent Pathway

  2026-06-22

  Liu et al. reveal that quinolinate phosphoribosyltransferase (QPRT) enhances breast cancer cell invasiveness by modulating myosin light chain phosphorylation through phospholipase C signaling. This mechanistic link between NAD+ metabolism and cytoskeletal dynamics highlights new opportunities for therapeutic targeting in aggressive breast cancers.

• Isoproterenol Sulfate Dihydrate in Human Cardiac Assembloid

  2026-06-22

  Isoproterenol sulfate dihydrate enables precise and reproducible modeling of beta-adrenergic signaling within advanced human cardiac assembloid systems. This article unpacks best-in-class experimental workflows, protocol enhancements, and troubleshooting strategies that maximize data quality for cutting-edge cardiovascular and GPCR signaling research.

• Erastin as a Ferroptosis Inducer: Optimizing Cancer Research

  2026-06-21

  Erastin stands out as a precision ferroptosis inducer, enabling researchers to selectively trigger iron-dependent cell death in RAS/BRAF-mutant cancers. This article details practical workflows, protocol advances, and troubleshooting strategies to help you harness Erastin’s full potential in oxidative stress and cancer biology research.

• LC-MS/MS Metabolomics Reveals Biomarkers of Carbapenem Resis

  2026-06-20

  This study applies LC-MS/MS metabolomics to profile the resistant phenotype of carbapenemase-producing Enterobacterales, identifying 21 metabolite biomarkers capable of distinguishing resistant from non-resistant isolates in under 7 hours. These findings advance rapid diagnostic strategies and provide mechanistic insights into antibiotic resistance development.

• Temafloxacin: Fluoroquinolone Antibacterial Agent for Advanc

  2026-06-19

  Temafloxacin empowers researchers with precision and flexibility in both in vitro and in vivo antibacterial workflows. Its potent inhibition of DNA gyrase and topoisomerase IV supports reproducible assays for Gram-positive, Gram-negative, and intracellular pathogens—setting a new benchmark for fluoroquinolone research compounds.

• Biochemical Roles of the CARMIL Membrane-Binding Domain in A

  2026-06-19

  The referenced study elucidates the multifaceted regulatory functions of the CARMIL membrane-binding (MB) domain in actin filament assembly at cellular membranes. By dissecting the interactions among CARMIL domains, capping protein (CP), and actin, the research advances our mechanistic understanding of cytoskeletal dynamics, with implications for the design of protein purification and interaction assays.

• (-)-Norepinephrine (+)-bitartrate in Cardiovascular Models

  2026-06-18

  (-)-Norepinephrine (+)-bitartrate is a benchmark adrenergic agonist enabling precise modeling of blood pressure and heart rate in preclinical cardiovascular and sepsis studies. This article details actionable workflows, troubleshooting insights, and critical advances revealed by recent research—ensuring reproducibility and rigor with APExBIO’s trusted reagent.

• N-octanoyl-L-Homoserine lactone: Reliable Tools for Infectio

  2026-06-18

  This article addresses key workflow challenges in infection biology and cancer–microbiota research, demonstrating how N-octanoyl-L-Homoserine lactone (SKU C3579) enables reproducible, data-rich experimentation. Scenario-driven recommendations highlight the compound’s role in quorum-sensing studies, cell viability assays, and translational projects, with actionable guidance for protocol optimization and vendor selection.

• Okadaic acid (A4540): Practical Guide for PP1 Inhibition Wor

  2026-06-17

  Okadaic acid is an established protein phosphatase 1 inhibitor best suited for controlled studies of phosphorylation-dependent signaling, apoptosis induction, and phosphatase inhibition in cellular or biochemical assays. It should be used with strict protocol adherence due to its nanomolar potency and is not recommended for exploratory or non-validated applications outside targeted pathway research.

• Novel FBN1 Mutation Linked to Severe Marfan Phenotype and Ao

  2026-06-17

  This case report details the discovery of a novel FBN1 frameshift-and-nonsense mutation associated with aggressive Marfan syndrome manifestations, including aortic dissection and skeletal abnormalities. The study underscores the importance of integrating genetic and clinical approaches for early diagnosis and risk stratification in Marfan syndrome.

• Dabigatran Etexilate: Direct Thrombin Inhibition Without CYP

  2026-06-16

  The reference study spotlights dabigatran etexilate as the first oral direct thrombin inhibitor that achieves predictable anticoagulant effects without involvement of the CYP3A metabolic pathway. This innovation addresses key limitations of traditional anticoagulants, reducing drug-drug interaction risk and simplifying clinical management in VTE and atrial fibrillation patients.

• Direct Mouse Genotyping Kit Plus: Rapid, High-Fidelity DNA E

  2026-06-16

  The Direct Mouse Genotyping Kit Plus enables rapid extraction and direct PCR amplification of mouse genomic DNA, eliminating purification steps and streamlining genotyping workflows. This kit, featuring a PCR master mix with dye reagents, supports routine genotyping, transgene detection, and gene knockout validation with high accuracy.

• EZ Cap™ Mouse IL-12 mRNA (m1Ψ): Engineering Precision Immune

  2026-06-15

  Explore the scientific underpinnings of EZ Cap™ Mouse IL-12 mRNA (m1Ψ) for immunotherapy research. This deep-dive unpacks mRNA engineering, delivery innovations, and practical assay considerations—distinctly focusing on mechanistic insights and translational impact.

• Enhancing Luteolin Bioavailability via P-gp Inhibition and S

  2026-06-15

  This study demonstrates a novel self-microemulsifying drug delivery system (SME) for luteolin that dramatically increases its oral bioavailability by inhibiting P-glycoprotein (P-gp) efflux. The approach has significant implications for improving the delivery and efficacy of poorly absorbed bioactive compounds, with strong translational relevance for pharmaceutical and nutraceutical development.

• (S)-Mephenytoin: CYP2C19 Substrate for Organoid Drug Metabol

  2026-06-14

  (S)-Mephenytoin, a gold-standard CYP2C19 substrate, enables precise modeling of human drug metabolism in hiPSC-derived intestinal organoids. This guide details practical workflows, troubleshooting, and the latest innovations that set APExBIO’s high-purity reagent apart for advanced pharmacokinetic studies.

556 records 14/38 page Previous Next First page 上5页 1112131415 下5页 Last page